Zoekresultaten - 13 results
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries
978-92-9498-674-0 Accession Number: NA URL: https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccine-effectiveness-hospitalisation.pdf Keywords: COVID-19 Multi-country Vaccine effectiveness Abstract: ...
Vaccine effectiveness of the second and third COVID-19 boosters in Belgium (administered during 2022 autumn campaign)
Matthieu Billuart; Toon Braeye Source: Sciensano, Brussels, Belgium, p.8 (2023) Accession Number: NA URL: https://covid-19.sciensano.be/sites/default/files/Covid19/Vaccine%20effectiveness%20of%20the%202nd%20 ...
Vaccinatiegraad en epidemiologische impact van de COVID-19-vaccinatiecampagne bij personen met onderliggende gezondheidsaandoeningen in België
Publication Type: Sci. report, recommendat°, guidance doc., directive, monograph Authors: Veerle Stouten; Matthieu Billuart; Izaak Van Evercooren; Pierre Hubin; Léonore Nasiadka; Lucy Catteau; Xavier Rygaert; Toon Braeye; Elias Vermeiren; Joris Van Loenho ...
Couverture vaccinale et impact épidémiologique de la campagne de vaccination COVID-19 chez les personnes présentant des maladies sous-jacentes en Belgique
Publication Type: Sci. report, recommendat°, guidance doc., directive, monograph Authors: Veerle Stouten; Matthieu Billuart; Izaak Van Evercooren; Pierre Hubin; Léonore Nasiadka; Lucy Catteau; Xavier Rygaert; Toon Braeye; Elias Vermeiren; Joris Van Loenho ...
Evaluation of quality and non-clinical data for licencing of vaccines
Publication Type: Scientific poster, presentation or proceeding Authors: Wim Van Molle Source: WHO GLO product evaluation course, NA, Issue WHO, NA (2013) Keywords: data EVALUATION Quality vaccine vaccines WHO Health Topics: Vaccin Vaccin Vaccin Efficaci ...
Regulatory issues regarding manufacture and control of vaccine adjuvants. The EU situation.
Publication Type: Scientific poster, presentation or proceeding Authors: Wim Van Molle; Koen Brusselmans; L. Tesolin; Geneviève Waeterloos Source: Modern Vaccines/adjuvants Formulation: Impact On Future Development, Meeting Management, Issue Herriot,J., V ...
Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.
1 and 2 months after infection. The capacity of exogenously given protein to boost the DNA-primed vaccination effect underlines the dominant role of Th1-type CD4 (+) helper T cells in ...
Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment.
M. tuberculosis challenge, as measured by reduced numbers of CFU in spleen and lungs, compared to animals vaccinated with control DNA. Gene gun immunization was not effective in either BALB /c or C57BL ...
Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A.
Publication Type: Peer reviewed scientific article Authors: Baldwin, S L; D'Souza, C D; Orme, I M; Liu, M A; Huygen, K; Denis, O; Tang, A; Zhu, L; Montgomery, D; Ulmer, J B Source: Tuber Lung Dis, Volume 79, Issue 4, Number 259, p.251-9 (1999) Keywor ...
Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex.
levels of interleukin (IL)-2, interferon-gamma, and TNF-alpha. Levels of IL-4, IL-6, and IL-10 were low or undetectable. Plasmid encoding Ag85C was not effective. Cytotoxic T cell activity was also ...